论文部分内容阅读
目的:评价多西他赛(D)联合拓扑替康(T)治疗晚期胃癌的临床疗效和毒性反应。方法:用DT方案治疗晚期胃痛患者47例。结果:可评价疗效者47例,完全缓解(CR)4例,占8.5%:部分缓解(PR)28例,占59.6%:稳定(SD)11例.占23.4%:进展(PD)4例,占8.5%。总有效率:(CR+PR)为68.1%,临床获益率(CR+PR+SD)为91.5%。中位肿瘤进展期(TTP)8.4个月,中位生存期(MST)12.8个月。主要不良反应为骨髓抑制、白细胞减少、胃肠道反应、恶心呕吐、腹泻、口腔粘膜炎,无治疗相关性死亡病例。结论:多西他赛联合拓扑替康治疗晚期胃癌临床缓解率颇高,提高了生存质量,不良反应可耐受,患者治疗依从性好,可以作为晚期胃癌一线治疗方案。
Objective: To evaluate the clinical efficacy and toxicity of docetaxel (D) combined with topotecan (T) in the treatment of advanced gastric cancer. Methods: Forty-seven patients with advanced gastric pain were treated with DT regimen. Results: 47 patients could evaluate the curative effect, 4 patients had complete remission (CR), accounting for 8.5%: partial response (PR) 28 cases, accounting for 59.6%: 11 cases of SD, 23.4% , Accounting for 8.5%. The total effective rate was (CR + PR) 68.1%, and the clinical benefit rate (CR + PR + SD) was 91.5%. The median tumor progression (TTP) was 8.4 months, and the median survival (MST) was 12.8 months. The main adverse reactions were myelosuppression, leukopenia, gastrointestinal reactions, nausea and vomiting, diarrhea, oral mucositis, and no treatment-related deaths. Conclusion: Docetaxel combined with topotecan in the treatment of advanced gastric cancer clinical remission rate is high, improve the quality of life, adverse reactions can be tolerated, patients with good compliance, can be used as a first-line treatment of advanced gastric cancer.